ISTH女性健康委员会调查:妊娠期COVID-19相关凝血病管理经验
结果显示妊娠期COVID-19相关凝血病(CAC)不常见,抗凝实践存在差异,部分CAC患者在接受预防性抗凝后仍发生静脉血栓栓塞。
要点
- 妊娠期CAC不常见,但一旦发生多较严重
- 低分子肝素是首选抗凝药,但剂量与疗程实践不一致
- 部分CAC患者预防性抗凝后仍发生血栓,需研究最佳方案
核心结论
- 在调查所报告的特定人群中,妊娠期COVID-19相关凝血病(CAC)不常见。
- 抗凝实践存在差异,可能未反映当前指南。
- 部分CAC患者在接受预防性抗凝(包括标准剂量和按体重调整剂量)后仍发生静脉血栓栓塞。
- 亟需研究确定妊娠期COVID-19感染者合适的抗凝剂量与疗程。
研究设计与样本
- 自填式调查,使用RedCap在线平台,由ISTH女性健康问题小组委员会支持。
主要发现
- 全部病例中1%发生CAC,其中65%分类为重度。
- 最常见的异常包括血小板减少、C反应蛋白升高、D-二聚体升高和淋巴细胞减少。
- 77%的受访者选择低分子肝素作为CAC抗凝药,其中60%使用标准预防剂量。
- 7例接受抗凝治疗的患者发生血栓,其中4例使用标准预防剂量、3例使用按体重调整剂量。
临床怎么用
- 低分子肝素为妊娠期CAC首选抗凝药,多数受访者使用标准预防剂量。
- 抗凝疗程应依据疾病严重程度和其他血栓危险因素确定。
- 需警惕预防性抗凝下仍可能发生静脉血栓栓塞。
局限性
- 数据来自问卷调查的特定报告人群,可能存在选择偏倚和报告偏倚。
- 抗凝实践存在差异,可能未反映当前指南。
- 妊娠期CAC相关数据本身有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) occurs following infection with the potentially fatal, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Infection can be complicated by coagulopathy, at times featuring thrombocytopenia and thrombosis alongside other coagulation abnormalities, also termed COVID-19-associated coagulopathy (CAC). Data concerning CAC in pregnancy are limited. Better understanding of physician experiences is essential to identify current practice patterns and knowledge gaps. OBJECTIVES: To determine physician experiences and practice patterns regarding CAC in pregnancy. METHODS: Self-administered survey using the RedCap online platform; supported by the ISTH Subcommittee on Women's Health Issues in Thrombosis and Hemostasis. RESULTS: Seventy-five respondents fully or partially completed the survey. Of 1546 reported cases, disease severity was specified in 1298. Sixty-four percent of COVID-19 infections were mild, whereas 4% were severe. Of all cases, 1% developed CAC, with 65% classified as severe. The most frequent abnormalities included thrombocytopenia, elevated C-reactive protein, D-dimer, and lymphopenia. Low molecular weight heparin was the anticoagulant of choice in CAC and was provided by 77% of respondents, with 60% using standard prophylactic dosing. Thrombosis occurred in seven anticoagulated patients who were receiving standard prophylactic (four) or weight-based (three) dosing. Disease severity and additional thrombosis risk factors dictated anticoagulation duration. CONCLUSION: In the select population reported by our survey, CAC appears to be uncommon in pregnancy. Anticoagulation practices vary and may not reflect current guidelines. Venous thromboembolism was observed in some CAC patients despite prophylactic anticoagulation (including standard and weight-adjusted dosing). Urgent research is required to determine appropriate anticoagulant dosing and duration in pregnant women with COVID-19 infection.
引用
- Jevtic SD, Malinowski AK, Othman M, et al. Physician experiences in management of COVID-19-associated coagulopathy in pregnancy: Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis. J Thromb Haemost. 2021. PMID: 34260818. doi:10.1111/jth.15462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。